XML 42 R28.htm IDEA: XBRL DOCUMENT v3.20.4
Stockholders' Equity, Common Stock Purchase Warrants, and Noncontrolling Interest (Tables)
12 Months Ended
Dec. 31, 2020
Equity [Abstract]  
Schedule of Outstanding Warrants to Purchase Common Stock

The common stock purchase warrants (classified in permanent equity) outstanding as of the dates indicated are as follows:

 

    Common Stock Purchase Warrants Issued and Outstanding at  
          Weighted           Weighted        
    December 31,    

Average

Exercise

    December 31,    

Average

Exercise

    Expiration  
    2020     Price /Share     2019     Price/Share     Date  
Series Z Warrants     16,814,939     $ 1.60       16,815,039     $ 1.60       April 2024  
UPO - Series Z Warrants     53,000     $ 1.60       53,000     $ 1.60       January 2022  
Series W Warrants     381,818     $ 5.00       381,818     $ 5.00       January 2022  
Series S Warrants         $       1,199,383     $ 0.01       June 2032  
Total     17,249,757     $ 1.68       18,449,240     $ 1.57          
Schedule of Noncontrolling Interest

The noncontrolling interest (“NCI”) included as a component of consolidated total stockholders’ equity is with respect to the Company’s majority-owned subsidiaries Lucid Diagnostics Inc. and Solys Diagnostics Inc., summarized for the periods indicated as follows:

 

    Year Ended
December 31, 2020
    Year Ended
December 31, 2019
 
NCI - equity (deficit) - beginning of period   $ (814 )   $ (161 )
Minority Interest investment -Solys Diagnostics Inc.           889  
Minority Interest share subscription receivable - Solys Diagnostics Inc.           (889 )
Lucid Diagnostics Inc. 2018 Equity Plan stock option exercise     5        
Net loss attributable to NCI - Lucid Diagnostics Inc.     (1,503 )     (801 )
Net loss attributable to NCI - Solys Diagnostics Inc.     (109 )     (10 )
Stock-based compensation expense - Lucid Diagnostics Inc. 2018 Equity Plan     52       158  
NCI - equity (deficit) - end of period   $ (2,369 )   $ (814 )